Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Adam on +44 1494 818 010 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Adam Woolley
Recruitment Consultant
+44 1494 818 010

Many thanks to all at Zenopa who have assisted me in securing my new role of Territory Manager for my new place of work, that I start in a week.
Russ, 2012

Astellas and Aveo report positive cancer drug data

4 January 2012 00:00 in Pharmaceutical Company Product News

Astellas and Aveo Pharmaceuticals have reported positive new clinical trial data from a study of tivozanib, their new therapy for advanced renal cell cancer.

The companies have conducted a phase III study of the drug called TIVO-1, in which it was compared to a leading alternative treatment among 517 patients with advanced renal cell carcinoma.

It was found that tivozanib was able to deliver statistically significant improvements in terms of progression-free survival to the control drug, which was an approved VEGF therapy.

Based on this data, Astellas and Aveo plan to submit the drug for regulatory approval in both the US and Europe at some point this year.

Dr Steven Ryder, president of Astellas Pharma global development, said: "We are delighted with the outcome of TIVO-1 and to be collaborating with Aveo on tivozanib at this critical juncture."

This comes after Astellas agreed to grant AstraZeneca an option for a pair of developmental diabetes therapies last month.ADNFCR-8000103-ID-801254532-ADNFCR

Other news stories from 04/01/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd